As tuberculosis reemerges as an important health problem worldwide, new drugs, better diagnostic tests and vaccines are being sought. In order to identify potentially useful peptides for the development of a synthetic vaccine against tuberculosis, immunological and functional studies were performed using proteins of the antigen 85 complex. Western blot (immuno-blot) analysis and a lymphoproliferation study was used to investigate the Band T-cell immune response of tuberculosis patients, healthy household contacts and normal controls to proteins of the Mycobacterium tuberculosis antigen 85 complex. Peptides derived from the 85A amino acid sequence were synthesized and used in fibronectin-binding and in ELISA assays. A peptide with the sequence CQPACRKAGCQTYKWEC bound to radiolabelled fibronectin in a time-dependent manner and was recognized by human sera in ELISA. This peptide was identified as a potential component of a synthetic vaccine against tuberculosis . 0001-7942 0 1993 SGM This work forms part of a thesis submitted by S . C. Leg0 to the Discipline of Cell Biology of the Escola Paulista de Medicina, in SZo Paulo, Brazil, in partial fulfilment of the requirement for the doctoral degree.
Introduction
The antigen 85 complex is a group of related mycobacterial proteins actively secreted into culture fluids. Three major components have been described by different authors and assigned different names. The P32 antigen described by De Bruyn et al. (1987) and by Borremanns et al. (1989) , as well as MPT44 and MPB44 from Nagai's classification of major mycobacterial culture fluid proteins (Nagai et al., 1981) correspond to antigen 85A of the classification proposed by Wiker et al. (1986~) . Both the a antigen cloned and sequenced by Matsuo et al. (1988) and the MPB59 protein, characterized by Wiker et al. (1986b) , correspond to 85B. Finally, the MPT45 and MPB45 antigens correspond to 85C (Nagai et al., 1991) .
In spite of the published data regarding the immunological response of tuberculosis, leprosy and AIDS patients to antigens of the 85 complex (Huygen et al., 1988; Rumschlag et al., 1988; Drabick & Baker, 1990) , the role these antigens play in the development of clinical * Author for correspondence. Tel. 57 1 233 9006; fax 57 1 280 3999.
Abbreviations: BCI/NBT, 5-bromo-4-chloro-3-indolyl phosphate/ nitroblue tetrazolium; FN, fibronectin. disease or protective immunity in humans is not yet clearly understood.
Components of antigen 85 complex were shown to be located in the outer cell wall and on the cell surface of Mycobacterium tuberculosis bacilli (Abou-Zeid et al., 1991 ; Rambukkana et al., 1991) and to participate in the binding of mycobacteria to fibronectin (FN)-coated surfaces . The binding capacity of antigen 85 to FN could have clinical as well as protective significance.
The phagocytosis of mycobacteria by monocytes/ macrophages could be influenced by the interaction between antigen 85 on the surface of mycobacteria, plasma FN, and FN receptors on the surface of the monocyte/macrophage. An immunological response against the 85 complex could interfere in this interaction, affecting the phagocytosis of the bacilli. Although antibodies are not considered to participate in the protective immunity against tuberculosis, it is possible that some degree of protection could be afforded by antibodies that effectively block the interaction between antigen 85 and FN.
The fact that immunization with live mycobacterial vaccine efficiently generates a protective response, while killed preparations do not (Orme, 1988) , is further evidence that proteins released by live bacilli are IP: 54.70.40.11
On: Thu, 02 May 2019 18:30:54 1544 S. C. LeGo, J . D. Lopes and M . E. Patarroyo important in the development of immunological protection. For the development of new vaccines against tuberculosis, the putative candidate antigens must be extensively studied.
The immunological response of patients, healthy household contacts and normal donors against the proteins of the antigen 85 complex was the main focus of the present work. We have identified a peptide derived from the 85A sequence which shows FN-binding activity and may consequently afford protective immunogenicity.
Methods
Mycobacteriwn tuberculosis proteins. M. tuberculosis H37Rv (TMC 102) was obtained from the Trudeau Mycobacterial Collection, Canada. Proteins were obtained by sonication as previously described (Parra et al., 1991) . Briefly, mycobacteria were grown in Sauton medium for 4-6 weeks, to confluence, recollected by filtration on a sintered glass filter and washed three times with phosphate-buffered saline (PBS). Sonication was performed in a Branson sonicator at 0 "C in four 15 min pulses. The sonic extract was subjected to ultracentrifugation at 150000g for 1 h at 4 "C. The supernatant was collected by puncturing the tube with a needle, avoiding the upper lipid layer. Protein concentration was estimated by the Lowry method.
Culture filtrate was obtained from 14-d cultures by filtration through a 0.22 pm filter and concentration in YM 10000 Amicon membranes.
Purified antigen 85B from M . tuberculosis (MPT59 protein) was kindly provided by Professor Morten Harboe (Institute of Immunology and Rheumatology, Oslo, Norway).
Subjects. Patients with pulmonary tuberculosis (as diagnosed by positive bacilloscopy and culture), and related household contacts, with no symptoms of tuberculosis, were selected at the Hospital Santa Clara, in Bogota. Normal controls were students from the Universidad Nacional de Colombia, Bogota, without known contact with tuberculosis. Blood samples were obtained after consent.
Western blots. Proteins from sonic extracts or the purified 85B protein were separated by SDS-PAGE and transferred onto nitrocellulose filters. Commercial molecular mass markers (Promega) or a composite of albumin, ovalbumin, thrombin and immunoglobulin light chains were used for calibration. The filters were incubated with the sera obtained from patients, contacts and controls, in a 1 : 100 dilution in TBST (10 mM Tris/HCl pH 7.5, 150 mM-NaC1,0.05 YO Tween 20) for 2 h and subsequently with alkaline-phosphatase-conjugated antihuman IgG antibodies (Promega) for 1 h. The reaction was developed with BCI/NBT (Promega).
After transfer from SDS-PAGE, nitrocellulose filters containing sonic extracts or culture filtrate were incubated with a 50 pg ml-' solution of FN in TBST for 2 h at room temperature, with biotinylated rabbit anti-FN antibodies (1 : 500) for 1 h and with streptavidinphosphatase (Sigma) 1 : 500 for 30 min, and were then developed with BCI/NBT. Rabbit anti-FN antibodies were kindly provided by Dr Ricardo Brentani (Ludwig Institute for Cancer Research, Brazil) and biotinylated according to Guesdon et al. (1979) .
Anti-85B antibodies. Strips of nitrocellulose containing the purified 85B protein were incubated with one of the sera recognizing it in Western blots. Anti-85B antibodies were eluted from the filter with 0 2 M-glycine pH 3.0 and neutralized with 1 ~-Tris/HCl pH 8.0, as described by Robinson et al. (1988) .
Lymphocyte proli$eration assay. Mononuclear cells were isolated from blood by centrifugation with Ficoll-Hypaque (d = 1077), and resuspended in RPMI 1640 culture medium (Flow Laboratories) supplemented with 2 mM-L-glutamine, 25 mM-HEPES, 10 ?LO (v/v) foetal calf serum, 100 IU penicillin ml-' and 40 pg gentamicin ml-'. The cells were distributed in 96-well flat-bottom culture plates (Falcon) at a concentration of 1-5 x lo5 per well, in triplicate. The proteins of the M . tuberculosis sonic extract were separated by preparative SDS-PAGE and transferred to a nitrocellulose filter. The bands of 28/29 kDa were identified by Western blotting with a positive serum and a horizontal strip of the filter containing these proteins was cut and used to stimulate lymphocytes. M. tuberculosis sonic extract and a strip of nitrocellulose filter without antigen were used as positive and negative controls, respectively. Cells with antigens were incubated for 5 d at 37 "C in humidified air containing 5 % (v/v) CO,. The cultures were then pulsed with 0.8 pCi (30 kBqj of [methyl-3H]thymidine (Amersham) for 16 h. The cells were harvested onto glass fibre filter strips and [methyl-3H]thymidine incorporation was measured in a liquid scintillation counter (Beckman L-9000). Stimulation indices were calculated by dividing the mean c.p.m. obtained for each serum in the wells containing antigen by the mean c.p.m. from wells stimulated with nitrocellulose without antigen. Lymphocyte proliferation to antigens or to whole sonic extract was considered positive when the stimulation index was at least three standard deviations above the mean of that obtained for the controls.
Peptide synthesis. Twenty-three peptides derived from the reported sequence for the 85A M . tuberculosis protein (Borremans et al., 1989) were synthesized by the solid-phase peptide synthesis method of Merrifield (1 963) and the simultaneous multiple solid-phase peptide synthesis method of Houghten (1985) . The amino acid sequences of these peptides are shown in Table 2 . Cysteines were added at both ends of each peptide to facilitate polymerization and to give better fixation on plates and filters.
FN-binding assay. Human plasma FN was purified from human plasma by affinity chromatography on a gelatin-Sepharose column (Pharmacia) according to Engvall & Ruoslahti (1977) . Protein concentration was determined after dialysis against PBS. The absence of contaminating proteins was verified by SDS-PAGE. FN was radiolabelled with lZ5I using Iodobeads (Pierce). Five microlitres of a 1 mM solution of each 85A peptide were dot-blotted on nitrocellulose filters, in triplicate, and the filters blocked with 10 mM-Tris/HCl pH 7.5, 150 mM-NaC1, 3 YO (v/v) Tween 20, plus 1 % (w/v) BSA (TBSTB), overnight at 4°C. Filters were then incubated with 50pg radiolabelled FN (specific activity 0.78 pCi pg-'; 29 kBq pg-') for 15, 30, 60 min or overnight. Excess FN was washed out with TBST, the dots cut from the filters and the radioactivity measured in a gamma counter. The means of the triplicates were calculated and the counts obtained from a void vial were subtracted.
FAST-ELISA. Sera of 15 patients with pulmonary tuberculosis, 15 household contacts and 15 controls were used in FAST-ELISA as follows. Lids from the Falcon Assay Screening Test System (Becton Dickinson Labware) were coated with 100 p1 of a 20 pg ml-' solution of peptide in PBS by vigorous agitation for 2.5 h. The lids were washed with PBS plus 0.1 % Tween 20 (PBST), then with demineralized water, and allowed to dry. The lids were incubated for 1 h with gentle agitation with a 1 : 20 dilution of each serum in PBST plus 5 YO (w/v) skimmed milk, in triplicate, then spray-washed with PBST and incubated for 1 h with anti-human IgG peroxidase conjugate (TAGO) 1 : 1000 in PBST with 5 % (w/v) milk. The reaction was developed with TMB peroxidase substrate (Kirkegaard & Perry Laboratories). The plates were read in an ELISA plate reader at a wavelength of 620 nm. Negative controls for the reactions were performed with lids incubated with an irrelevant peptide (peptide 24 in Table 2 ) and also by incubating lids with PBST and milk without serum. Positive controls for each peptide were represented by human sera giving absorbances greater than three standard deviations above the mean for the controls in a previous experiment. The absorbances obtained for each peptide in each group were compared by analysis of variance and the Tukey Studentized Range Method. 1991). By using eluted antibodies against antigen 85B in Western blots, two bands of 28 and 29 kDa were identified in a sonic extract of M . tuberculosis (Fig. 1) . Incubation of nitrocellulose strips containing sonic extract proteins with FN and biotinylated anti-FN antibodies revealed the same 28/29 kDa proteins. These results suggest that the proteins of 28/29 kDa correspond to components of the 85 family of FN-binding proteins.
Results
The components of the 85 family of antigens share a high level of homology and bind to FN (Abou-Zeid et al., Table 1 . Lymphocyte proliferation assay and recognition of 28/29 kDa proteins by Western blotting in 10 patients (1-lo), 9 healthy household contacts (11-19) , and 10 normal controls (20) (21) (22) (23) (24) (25) (26) (27) (28) (29) The stimulation index (SI) was calculated by dividing the mean of the counts from triplicate wells with antigen by the mean of the counts from wells without antigen. The mean SI for the control group stimulated with 28/29 kDa antigens was 0.784 (SD 0.27).
With sonic extract the mean SI for controls was 1.552 (SD 0.41).
Lymphoproliferation was taken as positive (*) for values 3 standard deviations above the mean SI from controls. The 28/29 kDa proteins were also present in culture filtrate (Fig. 1) .
Sera and mononuclear cells from ten patients, nine household contacts and ten controls were used for Western blots and lymphoproliferation assays. Fig. 2 shows that the bands of 28 and 29 kDa from M . tuberculosis sonic extract were recognized in Western blots by 7 of 9 patients, 2 of 9 contacts, and 3 of 9 controls. In the lymphoproliferation assay, stimulation indices above 1.59 for the 28/29 kDa antigens and above 2.78 for M . tuberculosis sonic extract were more than three standard deviations above the mean stimulation index obtained for controls, and were considered positive (Table 1) . According to these standards, lymphocytes from 4 of 9 patients, 1 of 8 contacts, and 0 of 8 controls proliferated when stimulated with the 28/29 kDa antigen. With the sonic extract, positive results were obtained with cells from 3 of 8 patients, 1 of 6 contacts, and 0 of 8 controls (Table 1) . These experiments show that the 28/29 kDa proteins present Band T-cell epitopes, and are recognized predominantly by patients with active disease.
Peptides derived from the 85A sequence were synthesized and used in a FN-binding assay, in order to identify the FN-binding domain of P32. Peptide 13, with the sequence CQPACRKAGCQTYKWEC, bound the radiolabelled FN in the first 15 min of incubation, and the binding increased proportionally with incubation time, from 15 to 60 min (Table 2) . With overnight incubation, non-specific binding appeared. The experiment was repeated three times with similar results. Peptides 5, 14 and 22 also displayed binding to FN after 15 min of incubation, increasing proportionally with incubation time. However, the c.p.m. obtained for peptide 13 were the highest at each incubation time. Peptides 5, 14 and 22 may represent secondary FNbinding sites with lower affinity.
In FAST-ELISA, peptide 13 was recognized by sera from patients, healthy household contacts and normal controls, with a higher A,,, than that obtained for all the other P32 peptides, or for an irrelevant peptide, in a similar assay ( Table 3 ). The absorbances obtained for each peptide were compared between the three groups of individuals by analysis of variance. No significant differences were found except for peptide 13 (DF = 2.73, I; = 9.82, P = 0.0002). Using the Tukey Studentized Range Method a significant difference at the 1% level was found for peptide 13 between the groups of patients and normal controls and between the groups of patients and healthy contacts. No significant difference was found between the groups of healthy contacts and normal controls.
Discussion
Using two different approaches, with anti-85B antibodies and FN, two bands of 28 and 29 kDa were identified in sonic extracts and culture filtrates of M . tuberculosis which correspond to components of the 85 family of FNbinding antigens.
The 85A and B proteins have been identified by others as 30 and 31 kDa proteins present in culture filtrates of different mycobacteria, and have not been detected in sonic extracts . In the present study, the proteins were also identified in the sonic extract; this could be related to differences in the Table 3 . FAST-ELISA with peptides from Table 2 The mean Ab2,-, was calculated from 25 patients, 25 healthy contacts and 25 controls. Standard deviations are shown in parentheses. The irrelevant peptide is peptide 24 in Table 2 . A significant difference in the recognition of peptide 13 was observed between the three groups by analysis of variance (DF = 2.73, F = 9.82, P = 0.0002) and between the group of patients and the two other groups using the Tukey Studentized Range Test at the 1 YO level.
Mean Aszo (SD) protocols used for its production. Abou-Zeid et al. (1988) postulated that these proteins must be present on the surface of the bacilli, as well as being secreted.
Recently, using monoclonal antibodies and sub-cellular fractions, Rambukkana et al. (199 1) confirmed the presence of proteins of the antigen 85 complex in the cell wall and on the cell surface of mycobacteria. These results agree with the detection of the 85 complex proteins by Western blots in sonic extracts. Pessolani & Brennan (1992) found no evidence of the FN-binding capacity of Mycobacterium leprae and BCG 85 complexes. They used FN, followed by anti-FN monoclonal antibody and alkaline-phosphataseconjugated secondary antibody in Western blots and dot blots. In the present study, no FN-binding activity was detected when a similar protocol was used : FN, followed by rabbit anti-FN antibodies and by alkalinephosphatase-conjugated goat anti-rabbit immunoglobulin G (Promega) (data not shown). It is possible that the structure with a secondary antibody became so large that it detached during the subsequent washing. The results shown in Fig. 1 were obtained with biotinylated anti-FN antibodies, bypassing the use of a secondary antibody. The results presented here confirm the previously observed FN-binding properties of proteins of the 85 complex.
The different molecular masses of our identified proteins could be related to the electrophoresis system used. Using two different standards, as described in Methods, the calculated molecular mass always corresponded to 28 and 29 kDa. Sera recognizing these two bands also recognized the purified 85B protein, with the same estimated molecular weight as the 28 kDa band (data not shown), suggesting that the lower band corresponds to MPT59, or 85B. Moreover, the Nterminal sequence of the 29 kDa band, purified by elution from acrylamide gels, corresponds to the homologous N-terminal sequence of the three 85 proteins ) (data not shown).
These proteins were recognized mainly by active pulmonary tuberculosis patients. Within this group, Bcell was more important than T-cell recognition. This is in accordance with previous observations showing that acutely ill tuberculosis patients present high titres of antibodies against mycobacterial proteins, and that these antibodies could play a role at the beginning of the infection (Falla et al., 1991 , David, 1990 .
Patients, healthy contacts and controls recognized the 28/29 kDa antigens in Western blots. As these proteins are shared among different strains of mycobacteria, it is possible that this recognition could be related to contact with environmental mycobacteria. Nevertheless, the difference in the recognition by active tuberculosis patients and the other groups is noteworthy, suggesting that the production of anti-85 antibodies could be related to the bacterial load. Harboe et al. (1990) demonstrated in animals that antibodies to the proteins of the 85 complex could be useful as a general indicator of mycobacterial infection. However, these antibodies would be of limited value for the specific diagnosis of M . tuberculosis infections in humans, because of the great cross-reactivity of these antigens between mycobacteria. However, the 85 antigens, or peptides derived from them, could be used as components of diagnostic assays together with other more specific antigens.
Regarding the lymphoproliferation studies, the stimulation indices obtained were low in general, indicating that the incorporation of thymidine did not increase significantly after in vitro stimulation of T cells with the antigens. The mean stimulation index from controls stimulated with 28/29 kDa antigens was less than 1, suggesting that these antigens might have an inhibitory effect upon the cells. There were more individuals from the patient group showing positive stimulation by 28/29 kDa antigens than individuals from contact or control groups, and similar results were observed with total sonic extracts.
These results indicate that the 85 complex proteins secreted by mycobacteria are immunogenic, this being a necessary condition for their use in the development of diagnostic tests and vaccines against tuberculosis. Although the cross-reactivity of these proteins between different species of mycobacteria would be a problem for diagnostic testing, this characteristic would be advantageous for the inclusion of the 85 complex proteins, or peptides derived from them, in a new generation of vaccines.
Using peptides derived from the sequence of 85A we identified one peptide -13 -involved in the FN-binding property of 85A. A sequence almost identical of that of peptide 13 is present in 85B, with two amino acid substitutions: Q for S and R for G in the first and fifth positions, respectively (Borremans et al., 1989) . In 85C, the amino acid sequence of this region is completely different (Content et al., 1991) . In fact, it is the largest motif (8 residues) in the entire sequence that differs significantly from the sequence of the other two proteins. It is noteworthy that while FN-binding activity has been described for both 85A and 85B, it has not yet been clearly demonstrated for 85C. This result, taken together with the results presented here, suggests that this amino acid sequence is related to the observed activity.
In the ELISA assay with synthetic peptides from 85A a significant difference in the recognition of peptide 13 was observed between the group of patients and the two other groups of healthy household contacts and normal controls. This is consistent with the preferential recognition of the 85 antigens by patients in Western blots and lymphoproliferation studies and suggests that peptide 13 could be a dominant epitope recognized by the individuals studied in these tests. Studies have yet to be done to determine the T-cell immunogenicity of this peptide as well as its protective potential in animal models.
If the interaction of M . tuberculosis bacilli with FN is an important pathogenic mechanism in tuberculosis, then an immunological response blocking this interaction could afford protection. We propose peptide 13, CQPACRKAGCQTYKWEC, as a good candidate component of a subunit synthetic vaccine against tuberculosis, together with other peptides derived from different immunogenic proteins of M . tuberculosis.
